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Cisapride is an oral prokinetic agentused for the symptomatic treatment
of nocturnal heartburn due to gastro-
esophageal reflux disease.1 It was first
approved in Korea in June 1989 and was
introduced to the US market in August
1993. Since cisapride’s introduction, 341
cases of ventricular arrhythmias, includ-
ing 80 deaths, have been reported to the
Food and Drug Administration (FDA).
Many of these cases had involved drugs
known to inhibit CYP3A4, which me-
tabolizes cisapride.2 Four label changes
and physician notifications (Dear Doctor
letters) were issued in February and Oc-
tober 1995, June 1998, and June 1999 in
the US.3 The Korean drug regulatory
agency modified cisapride’s label 3 times
in 2000 and distributed prescription guide-
lines to physicians. While such risk man-
agement efforts were being made, Janssen
Pharmaceutica, a major manufacturer of
cisapride, voluntarily discontinued com-
mercial marketing of the product in the
US in July 2000. Janssen Korea withdrew
the drug in October 2000.
After cisapride was withdrawn from
the general market, the manufacturer
provided it, with proper indication for its use, to patients
who were unresponsive to other therapies and had normal
electrocardiogram results.4 Apart from that specific use,
the distributors’ stocks of the drug also remained available
for general users, and no particular actions were taken on
generic products.
Concomitant use of cisapride and contraindicated drugs
can induce increased plasma cisapride concentrations and
QT interval prolongation.2,5 It also appeared to play an im-
portant role in adverse outcomes associated with serious, po-
tentially life-threatening ventricular tachyarrhythmias, such
as torsade de pointes.6-8 Moreover, the reported deaths were
directly or indirectly associated with an arrhythmic event.9
There has been a long history of serious adverse events
associated with the use of cisapride, and the majority of
Increase in Mortality Rate Following Coprescription of
Cisapride and Contraindicated Drugs
Nam-Kyong Choi, Seokyung Hahn, and Byung-Joo Park
Author information provided at the end of the text.
The Annals of Pharmacotherapy    n 2007 April, Volume 41   n 667www.theannals.com
BACKGROUND: No epidemiologic study, as of this writing, has been published on
the use of cisapride with contraindicated drugs and its relation to mortality rates in
a population-based setting. 
OBJECTIVE: To estimate the prevalence of concomitant use of cisapride with
contraindicated drugs and evaluate the association between this and the risk of
mortality.
METHODS: Claims data were obtained from the Health Insurance Review Agency
of Korea. The study population consisted of patients younger than 85 years who
visited clinics or hospitals in the city of Busan as new users of cisapride between
November 1, 2000, and April 30, 2002. The coprescription of cisapride was
defined as prescribing cisapride with one or more contraindicated drugs with the
same prescription. Nationwide mortality data were also used. The prevalence of
coprescribing cisapride was estimated and the association between this and the
risk of mortality was assessed by rate ratios (RRs). The RRs were estimated
using Cox’s regression model with time-dependent covariate, adjusted for age,
sex, and comorbidities. 
RESULTS: A total of 36 865 patients out of 56 012 claims were newly prescribed
cisapride; of these, 1175 patients (3.2%) were concomitantly prescribed at least
one contraindicated drug, which suggested adjusted mortality RRs of 14.08 (95%
CI 7.41 to 26.76) for recent users and 1.33 (95% CI 0.92 to 1.93) for past users of
cisapride.
CONCLUSIONS: Despite the discontinuation of the drug’s commercial marketing,
cisapride was still in use in clinics and hospitals in Busan. In many cases,
cisapride was co-prescribed with contraindicated drugs, which is associated with
increased mortality rates. 
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these cases involved contraindicated drugs. However, to
the best of our knowledge, there has been no published
epidemiologic study on the use of cisapride with con-
traindicated drugs and mortality in a population-based set-
ting. A properly designed study was necessary to identify
the risk of mortality associated with concomitant use of
cisapride and contraindicated drugs.
This study was conducted to estimate the prevalence of
the use of cisapride with contraindicated drugs and evalu-




Korea’s Health Insurance Review Agency (HIRA) was
established on July 1, 2000, to combine claims data review
and healthcare assessment, under the responsibility of a
single agency independent from insurers, providers, and
other interested parties. All Koreans are entitled to be ei-
ther an employed member or a community member under
the national health insurance system. When any beneficia-
ry demonstrates signs and/or symptoms that indicate a
need for medical care, the patient is provided with regional
medical services and the providers then submit claims to
the HIRA for a review of the incurred medical costs.
Therefore, the HIRA database contains all information on
claims made, as well as on prescriptions. 
We obtained a database containing claims data submit-
ted by health providers based in Busan under the condi-
tion of confidentiality on patient information. Our study
was exempt from review by the institutional review
board of Seoul National University Hospital at the time
of its planning, because it fell under the remission criteria
as a retrospective study using an existing dataset for aca-
demic purposes that did not involve personal informa-
tion. The data were provided after deleting the last digit
of each patient’s citizen registration number so that the
code could be used only for data sorting and linking pur-
poses without revealing the individual identity of each
patient. Only authorized researchers had access to the
database for analysis. 
The city of Busan is 450 kilometers southeast of Seoul,
the nation’s capital, and is the second largest city in Korea,
with a population of 3.81 million as of 2001. The
database includes the patients’ citizen registration num-
ber (without the last digit), age, sex, clinic registration
number, diagnosis, and list of prescribed drugs. The in-
formation provided on the drugs included brand name,
generic name, prescription date, and duration and route
of administration. Diagnoses were coded according to the
International Classification of Disease, Tenth Revision
(ICD -10).
COHORT
The study population was defined as patients younger
than 85 years who visited clinics or hospitals in the Busan
metropolitan area between November 1, 2000, and April
30, 2002, as new users of cisapride. New cisapride users
were defined as patients who took cisapride during this pe-
riod for the first time without a history of having been pre-
scribed the drug during the preceding 3 months. 
From nearly 20 million prescriptions with valid records
in the database, we identified every prescription of cis-
apride during the study period. All prescriptions relating to
the same patient were identified using the key based on the
citizen registration number and were linked together. We
extracted information on 55 393 patients and 93 608 rele-
vant prescriptions. We then excluded 18 528 patients who
did not meet the criteria (18 434 were not new cisapride
users and 94 were >85 y of age). The final study cohort in-
cluded 36 865 new cisapride users and 56 012 prescrip-
tions.
DRUG EXPOSURE 
Coprescription of cisapride was defined as the prescrip-
tion of cisapride with at least one contraindicated drug on
the same prescription. The contraindicated drugs that were
considered in the study were based on Notification No.
2004–2 announced by the Korea Ministry of Health and
Welfare (Table 1). The selection was made based on chem-
ical equivalency regardless of label or package. 
IDENTIFICATION OF DEATH
Nationwide mortality data from November 1, 2000, to
December 31, 2002, provided by the Korea National Sta-
tistical Office, were used. The data included the patient’s
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Table 1. Medications Contraindicated with Cisapridea
Therapeutic 
Category Medication
Anti-allergics astemizole, terfenadine, mequitazine, 
promethazine
Antiarrhythmics amiodarone HCl, disopyramide, procainamide, 
sotalol, quinidine, terfenadine
Antibacterial sparfloxacin
Antibiotics clarithromycin, erythromycin, erythromycin 
estolate, erythromycin stinoprate
Antidepressants amitriptyline HCl, fluvoxamine maleate, 
imipramine HCl, maprotiline, nefazodone
Antifungals fluconazole, itraconazole, ketoconazole
Antinausea prochlorperazine
Antipsychotics pimozide, perphenazine
Protease inhibitors indinavir, nelfinavir
aAnnounced by notification No. 2004–2 of the Korea Ministry of Health
and Welfare.
citizen registration number (without the last digit), cause of
death coded according to ICD -10 standards, and date of
death. All-cause mortality was defined as any disease-re-
lated death, excluding accidental deaths caused by traffic
accidents, other external causes of accidental injury, inten-
tional self-harm, and assaults. 
STATISTICAL ANALYSES 
The prevalence of the coprescription of cisapride was
estimated as the proportion of co-prescribed patients out of
the total number of new users of cisapride. The association
between cisapride coprescription and the risk of mortality
was measured by rate ratios (RRs). The RRs with 95%
confidence intervals were estimated using Cox’s regres-
sion model with time-dependent covariate. The point of
time for each coprescription was considered in the analysis
to account for a possible difference in the risk of death dur-
ing or outside the period of combined use. Consecutive
start and end times of co-prescriptions were recorded for
each subject to indicate every change in time-dependent
exposure over the study period. The model included one
time-dependent covariate (exposure) and several fixed co-
variates (confounders): 
log h(t) = α(t)+β1X1(t)+ β2X2+ β3X3+
β4X4+ β5X5+ β6X6+ β7X7
which estimates the hazard at time t depending on the val-
ue of X1 at t and on the values of X2, X3, X4, X5, X6, and
X7. X1(t) = 1 if on combined use at time t; 0 otherwise.
The follow-up time for each individual was from the
date of the first cisapride prescription until the earliest of
the following dates: death, 85th birthday, or December 31,
2002. The RRs were adjusted for age, sex, and comorbidi-
ties such as heart, respiratory system, and digestive system
disease, as well as neoplasms. Comorbidity data were con-
structed from records of diagnosis made at the time of cis-
apride prescription. Heart disease, respiratory system dis-
ease, digestive system disease, and neoplasms were de-
fined according to the ICD-10 diagnosis codes. 
We performed separate analysis that took into account
the time lapse between the time of last combined use and
time of death, adjusted for age, sex, and comorbidities. The
combined users were classified into 2 categories; recent
users (last combined use within 30 days of death) and past
users (beyond 30 days). Statistical analysis was performed
using the SAS statistical application program (Release 9.1,
SAS Institute Inc, Cary, NC).
Results 
A total of 36 865 patients were newly prescribed cis-
apride between November 1, 2000, and April 30, 2002; the
number of cisapride prescriptions administered to these pa-
tients was 56 012. Among the total cohort, 58.8% were fe-
male, with a mean ± SD age of 28.5 ± 24.1 years. Among
the new cisapride users, 1175 (3.2%) were prescribed at
least one contraindicated drug with cisapride, which made
up 1635 (2.9%) of the total claims. The 3 contraindicated
drugs most commonly co-prescribed with cisapride were
amitriptyline (486 claims), mequitazine (308), and terfena-
dine (292; Table 2). 
There was a significant age difference (p < 0.001) be-
tween the groups of cisapride users who were prescribed
contraindicated drugs and those who were not. Among the
new users of cisapride who did not take contraindicated
drugs, 48.6% were 0–24 years old and 9.2% were 65–84
years old. However, 27.5% of the co-prescribed users were
0–24 years old, and 17.9% were 65–84 years old. The
proportion of contraindicated drug users did not differ sig-
nificantly according to sex (p = 0.13) or comorbidities
such as respiratory system disease (p = 0.86) and neo-
plasms (p = 0.16). Comorbid digestive system disease was
more likely to be found in users who were not prescribed
contraindicated drugs (p < 0.001), and heart disease was
found more often in those prescribed contraindicated drugs
(p = 0.002; Table 3).
The frequency with which cisapride was co-prescribed
with contraindicated drugs varied throughout different age
groups. Patients aged 65–84 years had the highest preva-
lence of coprescription (6.0%), while the lowest preva-
lence (1.8%) was for the group aged 0–24 years. Among
patients with respiratory system diseases, 3.2% used con-
traindicated drugs. The prevalence of coprescribing cis-
apride with contraindicated drugs in those with digestive
system disease, heart disease, and neoplasms was 2.5%,
6.1%, and 4.4%, respectively (Table 3).
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Table 2. Frequency of Coprescribed Contraindicated
Medications Among New Users of Cisapride
Contraindicated 
Medication Pts., n (%)
Amitriptyline HCl 486 (28.8)
Mequitazine 308 (18.3)
Terfenadine 292 (17.3)




Imipramine HCl 43 (2.6)
Fluvoxamine maleate 39 (2.3) 
Ketoconazole 28 (1.7)
Itraconazole 18 (1.1) 
Amiodarone HCl 6 (0.4) 
Nefazodone 2 (0.1) 
Promethazine 1 (0.1) 
Sotalol 1 (0.1) 
Sparfloxacin 1 (0.1) 
TOTAL 1686 (100.0) 
The relationship between cisapride coprescription and
mortality risk is shown in Table 4. The total number of
deaths was 564. There had been no accidental deaths
found. Forty-four patients out of the 564 were co-pre-
scribed cisapride with contraindicated drugs, giving a
crude RR of 2.63 (95% CI 1.91 to 3.63). The adjusted RR
was 1.73 (95% CI 1.25 to 2.40). The adjusted RRs were
14.08 (95% CI 7.41 to 26.76) for recent cisiapride users
and 1.33 (95% CI 0.92 to 1.93) for past users.
Discussion
The results of this retrospective population-based cohort
study showed that, despite the discontinuation of the com-
mercial marketing of cisapride by Janssen Pharmaceutica,
cisapride was still newly prescribed to 36 865 patients in
the Busan area between November 1, 2000, and April 30,
2002. We also found that 3.2% of these patients were co-
prescribed cisapride with contraindicated drugs. The recent
coprescription of contraindicated drugs increased the risk
of all-cause mortality compared with the prescription of
cisapride without contraindicated drugs. However, the risk
was not significant after 30 days from the time of last com-
bined use. 
We observed that the concomitant users were older and
more likely to have heart disease than were those who
were not prescribed contraindicated drugs. This might be
related to the higher risk of mortality in those prescribed
contraindicated drugs. To minimize the possibility of such
confounding effects, we adjusted the results for age, sex,
and comorbidities; the overall adjusted RR became smaller
than the crude RR, but significantly greater than 1, sug-
gesting that interaction caused by the use of cisapride with
contraindicated drugs might contribute to death. We also
conducted a separate analysis based on the indication of
heart disease and the result showed that the combined use
was still a risk factor in patients who did not have heart
disease (adjusted RR 1.74; 95% CI 1.25 to 2.44). 
In order to investigate a causal relationship, it is impor-
tant to know whether the deaths occurred during at-risk pe-
riods. In our study, the status of the combined medication
use varied with time, and therefore an additional level of
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Table 4. Rate Ratios for Mortality by Time from Last Combined Prescription to Time of Death Among New Users of Cisapride
Person- Crude RR Adjusted RRa
Variable years Subjects, n Deaths, n (95% CI) (95% CI)
Cisapride without contraindicated drugs 57 650 35 690 520 1.00 1.00
Cisapride with contraindicated drugs 1873 1175 44 2.63 (1.91 to 3.63) 1.73 (1.25 to 2.40)
recent users (0 ≤ t ≤ 30 days) 8 13 10 118.94 (63.5 to 222.6) 14.08 (7.41 to 26.76)
past users (30 < t days) 1865 1162 34 1.99 (1.37 to 2.87) 1.33 (0.92 to 1.93)
aAdjusted for age, sex, respiratory system disease, digestive system disease, heart disease, and neoplasms using Cox’s regression model with time-
dependent covariate.
Table 3. Distribution of the Cisapride New Users
Prevalence of 
Pts., n (%) the Use of 
Cisapride with 
Cisapride Prescribed Without Cisapride Prescribed with Contraindicated
Variable Contraindicated Drugs Contraindicated Drugs p Valuea Drugs (%)
Age, y 28.1 ± 23.9b 39.9 ± 24.2b <0.001
0–24 17 360 (48.6) 323 (27.5) <0.001 1.8
25–44 8204 (23.0) 283 (24.1) 3.3
45–64 6827 (19.1) 359 (30.6) 5.0
65–84 3299 (9.2) 210 (17.9) 6.0
Sex
male 14 732 (41.3) 459 (39.1) 0.13 3.0
female 20 958 (58.7) 716 (60.9) 3.3
Comorbidities
respiratory system disease 15 036 (42.1) 498 (42.4) 0.86 3.2
digestive system disease 22 294 (62.5) 579 (49.3) <0.001 2.5
heart disease 306 (0.9) 20 (1.7) 0.002 6.1
neoplasms 366 (1.0) 17 (1.4) 0.16 4.4
TOTAL 35 690 (100.0) 1175 (100.0) 3.2
aBy Pearson’s χ2 test, or Student’s t-test, where appropriate.
bMean ± SD.
complexity was introduced due to the need to account for
time-dependent exposure in Cox’s regression model.10,11
Time-dependent covariates change in value over the
course of observation. Subgroup analyses were also per-
formed based on the time lapse between last combined use
and death. From the present results, we conclude that there
could be a link between the combined use of cisapride
with contraindicated drugs and death. 
Cisapride is metabolized by the CYP3A4 enzyme sys-
tem, and the concomitant use of drugs that inhibit these en-
zymes can increase plasma cisapride concentrations and
induce QT interval prolongation.2,5 In 1995, therefore, a
black box warning was added to the labeling on cisapride
products, stating that certain drugs that inhibit the enzymes
were contraindicated with cisapride because they could po-
tentially cause fatal arrhythmia; a list of the contraindicated
drugs was included with this warning.9
The combined use of cisapride with other medications
known to prolong the QT interval could also have additive
effects on QT interval.12 In June 1998, the use of class IA
and class III antiarrhythmic drugs and drugs known to pro-
long the QT interval, as well as certain medical conditions
(ie, history of prolonged QT intervals, ventricular arrhyth-
mia, ischemic heart disease, renal failure, congestive heart
failure, respiratory failure, uncorrected electrolyte disorders)
were added to the black box warning as contraindications.9
Several studies have reported the estimated prevalence
of coprescribing cisapride with contraindicated drugs. In
the US, a retrospective study of prescription claims from a
managed-care organization database for all patients with
cisapride prescriptions between July 1993 and December
1998 was conducted and published.13 Of 131 485 cisapride
prescriptions dispensed after the warnings began, 4414
(3.4%) overlapped with at least 1 contraindicated drug on
the labels at the time of the prescription. In the Nether-
lands, among cisapride users from 1994 to 1998, 944
(3.1%) patients used 1 or more potentially interacting
drugs.14 Compared with these studies, our study focused on
a specific period following the removal of cisapride from
the market; the results highlighted the fact that cisapride
was co-prescribed with contraindicated drugs after cis-
apride’s market withdrawal in proportions similar to those
found in the previous studies. 
Although our results were derived from an observation-
al study, the study’s strength is in the fact that it was the
first population-based study to investigate the association
between the coprescription of cisapride with contraindicated
drugs and mortality. We studied an entire target population,
rather than a sampled one, that was prescribed cisapride in a
chosen area during the study period. While several case re-
ports and postmarketing safety data have suggested the link
between cisapride and QT interval prolongation and torsade
des pointes,2,9,15,16 they did not evaluate the outcome of co-
prescribing cisapride with potential interacting drugs. 
When relying on spontaneous reports, it is not practical
to estimate population risks because considerable underre-
porting of adverse events is likely. For example, in the case
of arrhythmia, underreporting could be an even more seri-
ous factor because sudden cardiac deaths are often report-
ed without documentation of arrhythmia.9 Our study peri-
od was limited to the period following the discontinuation
of the commercial marketing of cisapride, which enabled
us to observe the impact of the discontinued marketing on
the use of the drug and estimate the prevalence of the use
of cisapride with contraindicated drugs. We restricted our
analysis to new users of cisapride, in order to maintain
control of the various underlying conditions of patients as
long-term users and of any possible bias in the selection
regarding early emergence symptoms, drug intolerance, or
treatment failure.17
Our results should also be interpreted with some limita-
tions in mind. Even though we tried to make adjustments
to minimize confounding effects, the information on po-
tential confounding factors that we used might not have
been complete. For example, we considered diagnoses as
reported to HIRA, which might differ from the patients’
actual diagnosis. A validation study compared the diagno-
sis derived from the HIRA database with the actual diag-
nosis in the patients’ medical records.18 Positive predictive
value (PPV) was calculated according to disease groups.
The PPV was 77.6% for neoplasm, 67.4% for stroke, and
58.6% for rheumatoid arthritis. The overall PPV of the di-
agnoses was 81.8% in the case of inpatients. However, the
diagnosis may not provide sufficient information on the
severity of individual disease status and medical history.
However, because the Korean drug regulatory agency had
already warned against the combined use of cisapride and
contraindicated drugs through new labels and by distribut-
ing prescription guides to physicians, any remaining con-
founders may have little impact.
We chose mortality as the event of interest. It might
have been more reasonable to consider serious ventricular
arrhythmia or prolongation of the QT interval as the out-
come to evaluate the effect of coprescription in cisapride
users. However, one known reason for the failure of previ-
ous observational studies19-22 to confirm or refute the asso-
ciation between cisapride and cardiac adverse events was
outcome misclassification.23 The difficulty of accurately
diagnosing QT prolongation would have had a significant
impact on misclassification. Furthermore, a variety of
terms were used for outcomes associated with cardiac toxi-
city, and it appeared that some relevant outcomes were of-
ten not included, thus contributing to the failure of these
studies in confirming the hypothesis. Mortality is clearly
defined and easily traceable to avoid such classification
problems, but it might be questionable for all-cause mor-
tality to be used as an outcome of a direct effect of the co-
prescription.
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Conclusions
We found that, despite the discontinuation of its com-
mercial marketing, cisapride was still in use through avail-
able sources; in many cases, it was co-prescribed with con-
traindicated drugs. Our findings also suggested that drug
interactions with the contraindicated co-prescribed drugs
might contribute to an increase in the risk of mortality. Cis-
apride has been withdrawn in most major markets, but it is
still used via a limited-access protocol. Cisapride should be
prescribed to carefully chosen patients and should not be
prescribed with contraindicated drugs. 
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EXTRACTO
TRASFONDO: No se había publicado un estudio epidemiológico sobre el
uso de cisapride concurrentemente con drogas contraindicadas y su
relación con tasas de mortalidad en un contexto poblacional.
OBJETIVOS: Estimar la prevalencia del uso de cisapride concurrentemente
con drogas contraindicadas y evaluar la asociación entre la prescripción
de cisapride concurrentemente con drogas contraindicadas y el riesgo de
mortalidad.
MÉTODOS: Se obtuvieron datos provenientes de reclamaciones ante la
Agencia Revisora del Seguro de Salud de Korea. La población bajo
estudio consistió de pacientes menores de 85 años de edad que visitaron
clínicas y hospitales en la ciudad de Busan como usuarios nuevos de
cisapride entre el primero de noviembre de 2000 y el 30 de abril de
2002. La prescripción concurrente de cisapride fue definida como
prescribir cisapride con una o más drogas contraindicadas en la misma
receta. También se utilizaron datos de mortalidad a nivel nacional. Se
estimó la prevalencia de la prescripción concurrente de cisapride y la
asociación entre la prescripción de cisapride concurrentemente con
drogas contraindicadas y el riesgo de mortalidad, fue evaluado mediante
razones de tasas. Las razones de tasas fueron estimadas usando el
modelo de regresión de Cox con variables dependientes del tiempo,
ajustadas por edad, género y comorbilidades.
RESULTADOS: De 56 012 reclamaciones, un total de 36 865 correspondían
a pacientes que eran usuarios nuevos de cisapride, de los cuales a 1175
pacientes (3.2%) se les prescribió por lo menos una droga
contraindicada concurrentemente con cisapride. Esto sugirió una razón
de tasas de mortalidad ajustada de 14.08 (IC 95% 7.41 y 26.76) para
usuarios recientes y 1.33 (IC 95% 0.92 y 1.93) para aquellos que habían
usado la droga en el pasado.
CONCLUSIONES: A pesar de que se descontinuó el mercadeo comercial de
la droga, cisapride aún sigue en uso y en muchos casos, es prescrita
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concurrentemente con drogas contraindicadas. Esta prescripción
concurrente está asociada con mortalidad.
Ana E Vélez
RÉSUMÉ
GÉNÉRALITÉS: Aucune étude épidémiologique n’a été publiée sur l’usage
du Cisapride avec des médicaments contre-indiqués et sa relation avec
les taux de mortalité sur une base de la population.
OBJECTIF: Estimer la prévalence de l’usage du Cisapride avec des
médicaments contre-indiqués et évaluer l’association entre la co-
prescription du Cisapride-médicaments contre-indiqués et le risque de
mortalité.
MÉTHODES: Des arguments de données furent obtenus à l’aide de l’
Agence de Surveillance de la Santé et des Assurances de la Corée du
Sud (HIRA). La population d’étude a consisté de patients de moins de
85 ans qui ont été consultés dans des cliniques ou hôpitaux de la ville de
Busan et qui ont été de nouveaux utilisateurs du Cisapride entre 1
novembre 2000 et 30 avril 2002. La co-prescription du Cisapride fut
définie comme prescrit avec un ou plusieurs médicaments contre-
indiqués et ce, sur la même ordonnance. Les données de mortalité à
l’échelle nationale furent également utilisées. La prévalence de la co-
prescription du Cisapride fut estimée et l’association entre la co-
prescription du Cisapride-médicaments contre-indiqués et le risque de
mortalité fut évaluée à l’aide du ratio des taux. Les ratios des taux furent
estimés en utilisant le modèle de régression de Cox utilisant une
covariable dépendante du temps, ajustée sur age, sexe, et comorbidités.
RÉSULTATS: Sur 56 012 demandes de remboursement, le Cisapride fut
nouvellement prescrit chez un total de 36 865 patients, parmi lesquels
1175 (3.2%) reçurent un médicament contre-indiqué avec le Cisapride
au moins une fois. Ceci suggère un taux de mortalité ajusté de 14.8%
(CI 95% 7.41 à 26.76) chez les utilisateurs récents et 1.33% (CI 95%
[0.92 à 1.93) chez les anciens utilisateurs.
CONCLUSIONS: En dépit de la suspension de la commercialisation du
médicament, le Cisapride a été toujours utilisé et, dans plusieurs cas, a
été coprescrit avec des médicaments contre-indiqués. La co-prescription
étant associée avec une mortalité.
Thierry Youmbi
Increased Mortality with Coprescription of Cisapride and Contraindicated Drugs
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